Skip to main content
letter
. 2024 Oct 14;14(1):177. doi: 10.1038/s41408-024-01154-z

Fig. 1. Risk and incidence of therapy-associated acute lymphoblastic leukemias in randomized controlled trials.

Fig. 1

Risk of t-ALL (A) with lenalidomide versus control in 18 RCTs. Events refers to the number of patients with acute lymphoblastic leukemia in regard to the total number of patients (intent-to-treat). Incidence of ALL (B) with lenalidomide treatment per 100 patients in 18 RCTs. CI Confidence Intervals, RCTs Randomized Controlled Trials, SCT Stem-Cell Transplantation, OR Odds Ratio.